Recommend maintenance therapy with lenalidomide in multiple myeloma

被引：3

作者：

Manasanch, Elisabet E. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77007 USA

来源：

SEMINARS IN ONCOLOGY | 2016年 / 43卷 / 06期

关键词：

Myeloma; Lenalidomide; Maintenance; Transplant; STEM-CELL TRANSPLANTATION; AUTOLOGOUS TRANSPLANTATION; THALIDOMIDE; SURVIVAL;

D O I：

10.1053/j.seminoncol.2016.11.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Thalidomide was the first immunomodulatory drug used as maintenance after autologous stem cell transplant (ASCT) in multiple myeloma (MM). This showed improved progression-free survival (PFS) and in some cases, overall survival (OS). Despite this, use of thalidomide was limited due to toxicity and high rates of therapy discontinuation. Lenalidomide, an analog of thalidomide, had a more favorable toxicity profile making its use in maintenance a potential approach. The use of lenalidomide as a maintenance therapy after ASCT in newly diagnosed MM patients has been investigated in four phase III randomized control studies. (C) 2016 Elsevier Inc. All rights reserved.

引用

页码：712 / 713

页数：2

共 50 条

[41] Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma
Sborov, Douglas W.
Benson, Don M.
Williams, Nita
Huang, Ying
Bowers, Mindy A.
Humphries, Kristina
Efebera, Yvonne
Devine, Steven
Hofmeister, Craig C.
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 (01) : 74 - 83
[42] Carfilzomib, lenalidomide, and dexamethasone maintenance for multiple myeloma: when and for whom?
Engelhardt, Monika
Waesch, Ralph
[J]. LANCET ONCOLOGY, 2023, 24 (02): : 118 - 119
[43] Maintenance Therapy With Lenalidomide Significantly Improved Survival Of Yong Newly Diagnosed Multiple Myeloma Patients
Gay, Francesca
Cavallo, Federica
Caravita, Tommaso
Cavalli, Maide
Nagler, Arnon
Montefusco, Vittorio
Pogliani, Enrico Maria
Buttignol, Silvia
Zamagni, Elena
Palladino, Carmela
Marcatti, Magda
Musto, Pellegrino
Catalano, Lucio
Baraldi, Anna
Carella, Angelo Michele
Afro, Anna Maria
Siniscalchi, Agostina
Crippa, Claudia
Vallone, Letizia Maria
Ciccone, Giovannino
Ben Yehuda, Dina
Di Raimondo, Francesco
Hardan, Izhar
Boccadoro, Mario
Palumbo, Antonio
[J]. BLOOD, 2013, 122 (21)
[44] Lenalidomide as maintenance for every newly diagnosed patient with multiple myeloma
Mateos, Maria-Victoria
Gonzalez de la Calle, Veronica
[J]. LANCET ONCOLOGY, 2019, 20 (01): : 5 - 6
[45] Lenalidomide Maintenance in Multiple Myeloma: A Retrospective, Nationwide, RealWorld Study
Harslof, Mads
Chanchiri, Iman
Silkjaer, Trine
Frolund, Ulf Christian
Teodorescu, Elena Manuela
Nielsen, Kristina Buchardi
Nielsen, Per Ishoy
Pedersen, Per Trollund
Iversen, Katrine Fladeland
Gronbaek, Kirsten
Vangsted, Annette J.
Thorsteinsdottir, Sigrun
Szabo, Agoston Gyula
[J]. BLOOD, 2023, 142
[46] Carfilzomib Induction with Lenalidomide and Clarithromycin Consolidation and Lenalidomide Maintenance (CarBiRD) for Multiple Myeloma (MM)
Forsberg, Peter A.
Rossi, Adriana C.
Pearse, Roger N.
Perry, Arthur
Pekle, Karen
Jayabalan, David
Ely, Scott
Coleman, Morton
Allan, John N.
Niesvizky, Ruben
Mark, Tomer
[J]. BLOOD, 2016, 128 (22)
[47] Multiple myeloma Proven advantage of continuous lenalidomide therapy
Arnheim, Katharina
[J]. ONKOLOGIE, 2010, 33 (12): : 718 - 719
[48] LENALIDOMIDE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Okada, K.
Okamoto, Y.
Tsukamoto, T.
Sugiura, H.
Matsui, H.
Ueda, T.
Jo, T.
Onishi, T.
Kunitomi, A.
Ueda, Y.
[J]. ANNALS OF ONCOLOGY, 2013, 24
[49] Early time therapy with Lenalidomide for advanced multiple myeloma?
Ronge, Renate
[J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2008, 133 (05) : 174 - 174
[50] Lenalidomide for Multiple Myeloma
Bertolini, Francesco
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (06): : 573 - 573

← 1 2 3 4 5 →